Premium
Inside Cover: A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis (Angew. Chem. Int. Ed. 50/2014)
Author(s) -
HernándezTorres Gloria,
Cipriano Mariateresa,
Hedén Erika,
Björklund Emmelie,
Canales Ángeles,
Zian Debora,
Feliú Ana,
Mecha Miriam,
Guaza Carmen,
Fowler Christopher J.,
OrtegaGutiérrez Silvia,
LópezRodríguez María L.
Publication year - 2014
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201410020
Subject(s) - monoacylglycerol lipase , endocannabinoid system , diacylglycerol lipase , lipase , chemistry , int , pharmacology , multiple sclerosis , enzyme , biochemistry , medicine , computer science , immunology , receptor , operating system
The inhibition of monoacylglycerol lipase (MAGL) the enzyme responsible for the inactivation of the endocannabinoid 2‐arachidonoylglycerol, is a strategy for the treatment of multiple sclerosis. In their Communication on page 13765 ff., M. L. López‐Rodríguez and co‐workers describe a potent, reversible, and selective inhibitor of MAGL that slows the clinical progression of multiple sclerosis without inducing undesirable CB 1 ‐mediated side effect.